2024
Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial
Lustberg M, Fan-Havard P, Wong F, Hill K, Phelps M, Herrera K, Tsai N, Synold T, Feng Y, Kalu C, Sedrak M, Yee L. Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial. Breast Cancer Research And Treatment 2024, 205: 61-73. PMID: 38280052, PMCID: PMC11062803, DOI: 10.1007/s10549-023-07223-4.Peer-Reviewed Original ResearchAI-induced arthralgiaBrief Pain Inventory-Short FormRandomized placebo-controlledPostmenopausal womenPlacebo-controlledBreast cancerDouble-blind pilot trialDouble-blind clinical trialGrip strengthReduced risk of recurrenceDiscontinuation of treatmentRisk of recurrenceGastrointestinal adverse effectsPilot trialPlasma curcuminInflammation-related conditionsPatient-reported outcome measuresSerum estradiolWell-toleratedEstrone levelsPurposeAromatase inhibitorsTreatment armsRandomized trialsT0-T3Study agents
2023
Design and methods of a translational, community-based, lifestyle weight management pilot intervention trial in breast cancer survivors with overweight or obesity
Haynam M, Chaplow Z, DeScenza V, Bowman J, Dispennette K, Zhang X, Kilar M, Hohn S, Fairman C, Lustberg M, Focht B. Design and methods of a translational, community-based, lifestyle weight management pilot intervention trial in breast cancer survivors with overweight or obesity. Contemporary Clinical Trials Communications 2023, 33: 101154. PMID: 37250507, PMCID: PMC10220259, DOI: 10.1016/j.conctc.2023.101154.Peer-Reviewed Original ResearchBreast cancer survivorsLifestyle weight management interventionsWeight management programWeight management interventionsPilot trialCancer survivorsPreliminary efficacyPilot intervention trialPatient-reported outcomesLifestyle behavior changeSignificant weight gainBreast cancer treatmentMode of deliveryCommunity-based intervention modelMulti-component interventionCommunity-based interventionsQuality of lifeTrial feasibilityDietary modificationCardiometabolic diseasesIntervention trialsCancer recurrenceEfficacy trialsOverweightWeight gain
2021
Preliminary efficacy of a community-based, group-mediated cognitive behavioral lifestyle intervention among breast cancer survivors.
Haynam M, Fairman C, Bowman J, DeScenza V, Chaplow Z, Kilar M, Dispennette K, Hohn S, Zhang X, Lustberg M, Focht B. Preliminary efficacy of a community-based, group-mediated cognitive behavioral lifestyle intervention among breast cancer survivors. Journal Of Clinical Oncology 2021, 39: e24035-e24035. DOI: 10.1200/jco.2021.39.15_suppl.e24035.Peer-Reviewed Original ResearchBCa survivorsBreast cancer survivorsPhysical functionPreliminary efficacyBody compositionCancer survivorsPilot trialPost-treatment weight gainDual-energy X-ray absorptiometryCognitive behavioral lifestyle interventionCognitive outcomesDietary weight lossPercent lean massBehavioral lifestyle interventionSupportive care approachesLifestyle weight management interventionsWeight management interventionsSuccessful weight managementX-ray absorptiometrySelf-reported outcomesLifestyle interventionMetabolic syndromeWalk testLifestyle behaviorsWeight management
2014
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Berger M, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro C, Lustberg M. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2014, 23: 2019-2024. PMID: 25519756, PMCID: PMC4804339, DOI: 10.1007/s00520-014-2556-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDexamethasoneDiphenhydramineDrug Administration ScheduleDrug HypersensitivityFamotidineFemaleHumansInfusions, IntravenousMiddle AgedNeoplasm StagingPaclitaxelPremedicationProspective StudiesRetrospective StudiesConceptsInfusion hypersensitivity reactionPaclitaxel-based chemotherapyRescue medication useBreast cancer patientsHypersensitivity reactionsPaclitaxel dosesRescue medicationMedication useSecond doseCancer patientsBreast cancerLife-threatening complicationsMajority of patientsDoses of paclitaxelProspective pilot trialUse of paclitaxelBreast cancer treatmentPrimary endpointInfusion reactionsPremedication regimenSubsequent dosesUnwanted side effectsResultsIn totalPilot trialStudy population